Cancer immunotherapy involves empowering the patient’s immune system to recognize, attack and destroy cancer cells.
Since cancer cells arise from healthy cells, it can be hard for the immune system to differentiate them. There are several immunotherapeutic strategies to overcome this challenge, including vaccines, which aim to spark immune recognition and response to the tumor. Another approach, called adoptive cell transfer, entails removing and re-injecting the patient with their own immune cells, specially trained to recognize the cancer cells.
Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.